Tuberculosis and Respiratory Diseases

The Korean Academy of Tuberculosis and Respiratory Diseases (대한결핵및호흡기학회)
권호 표지
DOI QR코드

DOI QR Code

The Clinical Efficacy and Safety of Four-Weekly Docetaxel as First-Line Therapy in Elderly Lung Cancer Patients with Squamous Cell Carcinoma

  • Choi, Jong Hyun (Department of Internal Medicine, Korea University Guro Hospital) ;
  • Choi, Juwhan (Department of Internal Medicine, Korea University Guro Hospital) ;
  • Chung, Sang Mi (Department of Internal Medicine, Korea University Guro Hospital) ;
  • Oh, Jee Youn (Department of Internal Medicine, Korea University Guro Hospital) ;
  • Lee, Young Seok (Department of Internal Medicine, Korea University Guro Hospital) ;
  • Min, Kyung Hoon (Department of Internal Medicine, Korea University Guro Hospital) ;
  • Hur, Gyu Young (Department of Internal Medicine, Korea University Guro Hospital) ;
  • Shim, Jae Jeong (Department of Internal Medicine, Korea University Guro Hospital) ;
  • Kang, Kyung Ho (Department of Internal Medicine, Korea University Guro Hospital) ;
  • Lee, Hyun Kyung (Department of Internal Medicine, Inje University Busan Paik Hospital) ;
  • Lee, Sung Yong (Department of Internal Medicine, Korea University Guro Hospital)
  • Received : 2018.05.30
  • Accepted : 2018.10.12
  • Published : 2019.07.31
Download PDF
⟨ Previous Next ⟩

Abstract

Background: Docetaxel is one of the standard treatments for advanced non-small cell lung cancer. Docetaxel is usually administered in a 3-week schedule, but there is significant toxicity. In this phase II clinical study, we investigated the efficacy and safety of a 4-weekly schedule of docetaxel monotherapy, as first-line chemotherapy for advanced squamous cell carcinoma in elderly lung cancer patients. Methods: Patients with stage IIIB/ IV lung squamous-cell carcinoma age 70 or older, that had not undergone cytotoxic chemotherapy were enrolled. Patients received docetaxel $25mg/m^2$ on days 1, 8, and 15, every 4 weeks. Primary endpoint was the objective response rate (ORR). Secondary endpoints were progression-free survival (PFS), overall survival (OS), and toxicity profiles. Results: A total of 19 patients were enrolled. Among 19 patients, 17 were for evaluated efficacy and safety. In the intent-to-treat population, ORR and disease control rate (DCR) were 11.8% and 47.1%, respectively. In the response evaluable population, ORR was 16.7% and DCR was 66.7%. Median PFS and OS were 3.1 months and 3.3 months, respectively. There were three adverse grade 3/4 events. Grade 1 neutropenia was reported in one patient. Conclusion: Our data failed to demonstrate efficacy of a 4-weekly docetaxel regimen, in elderly patients with a poor performance status. However, incidence of side effects, including neutropenia, was lower than with a 3-week docetaxel regimen, as previously reported.

Keywords

References

  1. Livingston RB. Current management of unresectable nonsmall cell lung cancer. Semin Oncol 1994;21(5 Suppl 10):4-11.
  2. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8. https://doi.org/10.1056/NEJMoa011954
  3. Sekine I, Saijo N. Novel combination chemotherapy in the treatment of non-small cell lung cancer. Expert Opin Pharmacother 2000;1:1131-61. https://doi.org/10.1517/14656566.1.6.1131
  4. Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997;15:2996-3018. https://doi.org/10.1200/JCO.1997.15.8.2996
  5. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373:1627-39. https://doi.org/10.1056/NEJMoa1507643
  6. Peters S, Gettinger S, Johnson ML, Janne PA, Garassino MC, Christoph D, et al. Phase II trial of atezolizumab as first-line or subsequent therapy for patients with programmed deathligand 1-selected advanced non-small-cell lung cancer (BIRCH). J Clin Oncol 2017;35:2781-9. https://doi.org/10.1200/JCO.2016.71.9476
  7. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med 2016;375:1823-33. https://doi.org/10.1056/NEJMoa1606774
  8. Fossella FV, DeVore R, Kerr RN, Crawford J, Natale RR, Dunphy F, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced nonsmall-cell lung cancer previously treated with platinumcontaining chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-62. https://doi.org/10.1200/JCO.2000.18.12.2354
  9. Kudoh S, Takeda K, Nakagawa K, Takada M, Katakami N, Matsui K, et al. Phase III study of docetaxel compared with vinorelbine in elderly patients with advanced non-small-cell lung cancer: results of the West Japan Thoracic Oncology Group Trial (WJTOG 9904). J Clin Oncol 2006;24:3657-63. https://doi.org/10.1200/JCO.2006.06.1044
  10. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103. https://doi.org/10.1200/JCO.2000.18.10.2095
  11. Bansal P, Osman D, Gan GN, Simon GR, Boumber Y. Recent advances in targetable therapeutics in metastatic non-squamous NSCLC. Front Oncol 2016;6:112.
  12. Kudo S, Hino M, Fujita A, Igarashi T, Arita K, Niitani H, et al. Late phase II clinical study of RP56976 (docetaxel) in patients with non-small cell lung cancer. Gan To Kagaku Ryoho 1994;21:2617-23.
  13. Hainsworth JD, Burris HA 3rd, Litchy S, Morrissey LH, Barton JH, Bradof JE, et al. Weekly docetaxel in the treatment of elderly patients with advanced nonsmall cell lung carcinoma. A Minnie Pearl Cancer Research Network Phase II Trial. Cancer 2000;89:328-33. https://doi.org/10.1002/1097-0142(20000715)89:2<328::AID-CNCR17>3.0.CO;2-F
  14. Gridelli C, Gallo C, Di Maio M, Barletta E, Illiano A, Maione P, et al. A randomised clinical trial of two docetaxel regimens (weekly vs 3 week) in the second-line treatment of nonsmall-cell lung cancer. The DISTAL 01 study. Br J Cancer 2004;91:1996-2004. https://doi.org/10.1038/sj.bjc.6602241
  15. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47. https://doi.org/10.1016/j.ejca.2008.10.026
  16. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86. https://doi.org/10.1002/ijc.29210
  17. Rossi A, Gridelli C. Chemotherapy of advanced non-small cell lung cancer in elderly patients. Ann Oncol 2006;17 Suppl 2:ii58-60. https://doi.org/10.1093/annonc/mdj925
  18. Lilenbaum RC. Treatment of advanced non-small-cell lung cancer in special populations. Oncology (Williston Park) 2004;18:1321-5.
  19. Midha A, Dearden S, McCormack R. EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). Am J Cancer Res 2015;5:2892-911.
  20. Kim KS, Oh IJ, Ban HJ, Cho HJ, Kwon YS, Kim YI, et al. Comparison of docetaxel/cisplatin dosages of 75/60 and 60/60 mg/m(2) for the treatment of non-small cell lung cancer. Exp Ther Med 2012;4:317-22. https://doi.org/10.3892/etm.2012.597
  21. Du Z, Qing J, Ye H, Zhang Z, Lu J. Effects of weekly dose docetaxel monotherapy schedule for elderly patients with non-small cell lung cancer. Chinese-German J Clin Oncol 2009;8:9. https://doi.org/10.1007/s10330-008-0148-2
  22. Lilenbaum R, Rubin M, Samuel J, Boros L, Chidiac T, Seigel L, et al. A randomized phase II trial of two schedules of docetaxel in elderly or poor performance status patients with advanced non-small cell lung cancer. J Thorac Oncol 2007;2:306-11. https://doi.org/10.1097/01.JTO.0000263713.38826.8e
  23. Groopman JE, Itri LM. Chemotherapy-induced anemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616-34. https://doi.org/10.1093/jnci/91.19.1616

Cited by

  1. Development and Internal Validation of a Nomogram Used to Predict Chemotherapy-Induced Neutropenia in Non-Small Cell Lung Cancer Patients: A Retrospective Cohort Study vol.13, 2019, https://doi.org/10.2147/cmar.s302722